Solid Biosciences (SLDB) Free Cash Flow Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 88.70% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 66.37% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 3.98% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 137.65% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -48.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.00% |
| Dec 31, 2025 | -79.92% |
| Sep 30, 2025 | -40.36% |
| Jun 30, 2025 | -77.31% |
| Mar 31, 2025 | -26.00% |
| Dec 31, 2024 | -32.55% |
| Sep 30, 2024 | -33.61% |
| Jun 30, 2024 | 21.26% |
| Mar 31, 2024 | 11.09% |
| Dec 31, 2023 | 35.79% |
| Sep 30, 2023 | 11.42% |
| Jun 30, 2023 | -67.14% |
| Mar 31, 2023 | -3.81% |
| Dec 31, 2022 | -70.90% |
| Sep 30, 2022 | -5.52% |
| Jun 30, 2022 | 5.25% |
| Mar 31, 2022 | -28.28% |
| Dec 31, 2021 | -1,732.48% |
| Sep 30, 2021 | -21.44% |
| Jun 30, 2021 | -24.25% |
| Mar 31, 2021 | 27.03% |
| Dec 31, 2020 | 105.70% |
| Sep 30, 2020 | 21.35% |
| Jun 30, 2020 | 49.81% |
| Mar 31, 2020 | -5.20% |
| Dec 31, 2019 | -0.22% |
| Sep 30, 2019 | -71.68% |
| Jun 30, 2019 | -40.38% |
| Mar 31, 2019 | -53.41% |
| Dec 31, 2018 | -77.63% |
| Sep 30, 2018 | -4.66% |
| Jun 30, 2018 | -97.25% |
| Mar 31, 2018 | -77.96% |